JP4527408B2 - ムスカリン性アンタゴニスト - Google Patents

ムスカリン性アンタゴニスト Download PDF

Info

Publication number
JP4527408B2
JP4527408B2 JP2003587783A JP2003587783A JP4527408B2 JP 4527408 B2 JP4527408 B2 JP 4527408B2 JP 2003587783 A JP2003587783 A JP 2003587783A JP 2003587783 A JP2003587783 A JP 2003587783A JP 4527408 B2 JP4527408 B2 JP 4527408B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
group
mmol
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003587783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006507220A5 (enExample
JP2006507220A (ja
Inventor
クレイグ ディー． ボイル，
ウィリアム ジェイ． グリーンリー，
サミュエル チャカラマンニル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2006507220A publication Critical patent/JP2006507220A/ja
Publication of JP2006507220A5 publication Critical patent/JP2006507220A5/ja
Application granted granted Critical
Publication of JP4527408B2 publication Critical patent/JP4527408B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003587783A 2002-04-26 2003-04-24 ムスカリン性アンタゴニスト Expired - Fee Related JP4527408B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37609302P 2002-04-26 2002-04-26
PCT/US2003/012694 WO2003091220A1 (en) 2002-04-26 2003-04-24 Muscarinic antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009285736A Division JP2010059213A (ja) 2002-04-26 2009-12-16 ムスカリン性アンタゴニスト

Publications (3)

Publication Number Publication Date
JP2006507220A JP2006507220A (ja) 2006-03-02
JP2006507220A5 JP2006507220A5 (enExample) 2006-05-25
JP4527408B2 true JP4527408B2 (ja) 2010-08-18

Family

ID=29270760

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003587783A Expired - Fee Related JP4527408B2 (ja) 2002-04-26 2003-04-24 ムスカリン性アンタゴニスト
JP2009285736A Withdrawn JP2010059213A (ja) 2002-04-26 2009-12-16 ムスカリン性アンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009285736A Withdrawn JP2010059213A (ja) 2002-04-26 2009-12-16 ムスカリン性アンタゴニスト

Country Status (11)

Country Link
US (1) US6890936B2 (enExample)
EP (1) EP1499596B1 (enExample)
JP (2) JP4527408B2 (enExample)
CN (1) CN1649845A (enExample)
AT (1) ATE413388T1 (enExample)
AU (1) AU2003228674A1 (enExample)
CA (1) CA2484217A1 (enExample)
DE (1) DE60324544D1 (enExample)
ES (1) ES2315494T3 (enExample)
MX (1) MXPA04010552A (enExample)
WO (1) WO2003091220A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1622569T3 (pl) 2003-04-24 2016-06-30 Incyte Holdings Corp Pochodne aza spiro alkanów jako inhibitory metaloproteaz
WO2006034089A1 (en) * 2004-09-20 2006-03-30 Targacept, Inc. Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20080103105A1 (en) * 2006-09-22 2008-05-01 Braincells, Inc. HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
WO2008039863A2 (en) * 2006-09-27 2008-04-03 Braincells, Inc. Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2011143457A2 (en) 2010-05-12 2011-11-17 Northwestern University Compositions and methods for treating or preventing atrial fibrillation
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
CN107108597B (zh) 2014-10-31 2020-04-17 英立维尔英国有限公司 多巴胺d3受体拮抗剂化合物
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
KR20200027992A (ko) * 2017-07-12 2020-03-13 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
WO2019126559A1 (en) * 2017-12-20 2019-06-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04225953A (ja) * 1990-05-07 1992-08-14 Shionogi & Co Ltd スピロ　ジベンゾスベラン誘導体
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
WO1999032489A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
EP1386920A4 (en) * 2001-04-20 2005-09-14 Banyu Pharma Co Ltd benzimidazolone derivatives

Also Published As

Publication number Publication date
US6890936B2 (en) 2005-05-10
MXPA04010552A (es) 2005-01-25
EP1499596A1 (en) 2005-01-26
JP2006507220A (ja) 2006-03-02
US20040067972A1 (en) 2004-04-08
HK1068136A1 (en) 2005-04-22
CN1649845A (zh) 2005-08-03
EP1499596B1 (en) 2008-11-05
AU2003228674A1 (en) 2003-11-10
JP2010059213A (ja) 2010-03-18
ATE413388T1 (de) 2008-11-15
DE60324544D1 (de) 2008-12-18
ES2315494T3 (es) 2009-04-01
WO2003091220A1 (en) 2003-11-06
CA2484217A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
JP4527408B2 (ja) ムスカリン性アンタゴニスト
JP4448134B2 (ja) ベンズアミド置換基を有する環状アミンｂａｓｅ−１阻害剤
AU688120B2 (en) New piperidine compounds, process for their preparation and the pharmaceutical compositions which contain them
KR101432112B1 (ko) 도파민 ｄ3 수용체 리간드로서의 신규 카보닐화된 (아자)사이클로헥산
EP2010506B1 (en) Diazepan derivatives modulators of chemokine receptors
JP2009155350A (ja) ムスカリン性アンタゴニストとしてのピペリジン化合物
JP2004512324A (ja) Ｎｍｄａ受容体拮抗剤としてのアミド誘導体
AU9206798A (en) Pyrrolidine and piperidine modulators of chemokine receptor activity
JP2009167218A (ja) Ｍｃｈアンタゴニストおよび肥満治療でのそれらの使用
CN1481361A (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
HRP20000495A2 (en) N-acyl cyclic amine derivatives
JP2006502181A (ja) ５−ｈｔ４レセプターアゴニストとしてのイミダゾピリジン化合物
ZA200700329B (en) New heterocyclic carboxylic acid amide derivatives
KR101567116B1 (ko) Ｎｋ1 수용체 길항제로서의 5-[5-[2-(3,5-비스(트리플루오로메틸)페닐)-2-메틸프로파노일메틸아미노]-4-(4-플루오로-2-메틸페닐)]-2-피리디닐-2-알킬-프롤린아미드
US6916822B2 (en) Phenoxyalkylamine derivatives useful as opioid δ receptor agonists
ZA200700322B (en) New benzoyl urea derivatives
JP4605801B2 (ja) 肥満治療用のｍｃｈアンタゴニスト
DE69529790T2 (de) Imidazolin-Derivate, deren Herstellung und deren Verwendung als Tachykinin-Rezeptor Antagonisten
US20090029979A1 (en) 5-htx modulators
HK1068136B (en) Muscarinic antagonists
JPWO2005030722A1 (ja) Ｎ−置換−ｎ−（４−ピペリジニル）アミド誘導体
EP1910316B1 (en) Substituted triazole derivatives and their use as neurokinin 3 receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100527

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100603

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130611

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees